Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Metastatic Breast Cancer|Locally Advanced HER2 Positive Breast Carcinoma
Interventions: DRUG: Tucatinib|DRUG: Trastuzumab|DRUG: Vinorelbine
Sponsor: Spanish Breast Cancer Research Group
Collaborators: Seagen Inc.